Cargando…
Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial
BACKGROUND: The monthly continuous erythropoietin receptor activator (CERA) utilization maintains stable hemoglobin (Hb) after conversion from weekly epoetin-β (EB); however, how the different pharmacologic properties affect the red blood cell (RBC) size determined by RBC distribution width (RDW) ha...
Autores principales: | Uriol-Rivera, Miguel G., Obrador-Mulet, Aina, Jimenez-Mendoza, Sonia, Corral-Baez, Antonio, Perianez-Parraga, Leonor, Garcia-Alvarez, Angel, de la Prada, Francisco J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734489/ https://www.ncbi.nlm.nih.gov/pubmed/35059087 http://dx.doi.org/10.14740/jh862 |
Ejemplares similares
-
Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014) -
The Relation of Erythropoietin Towards Hemoglobin and Hematocrit in Varying Degrees of Renal Insufficiency
por: Panjeta, Mirsad, et al.
Publicado: (2015) -
The cost-utility of treating anemia with continuous erythropoietin receptor activator or Epoetin versus routine blood transfusions among chronic hemodialysis patients
por: Maoujoud, Omar, et al.
Publicado: (2016) -
Gender Differences in Dose of Erythropoietin to Maintain Hemoglobin Target in Hemodialysis Patients
por: Coronado Daza, J. A., et al.
Publicado: (2019) -
Association of Anisocytosis with Markers of Immune Activation and Exhaustion in Treated HIV
por: Al-Kindi, Sadeer G., et al.
Publicado: (2017)